Overview

Chemomab is a clinical-stage biotech company, focusing on discovery and development of innovative therapeutics for fibrosis-related diseases with large unmet need.

The company’s lead candidate, CM-101, is a first-in-class monoclonal antibody that targets CCL24 and was shown to interfere with the underlying biology of liver, skin and lung fibrosis using a novel and differentiated mechanism of action.

Chemomab is currently promoting in parallel three phase 2 studies, focusing on the rare indications primary sclerosing cholangitis (PSC) and systemic sclerosis (SSc).

Recent News
Aug 12, 2022

─Chemomab to Host Webcast and Conference Call for Investors Today, August 12 at 8:00 am ET─ TEL AVIV, Israel, Aug. 12, 2022 /PRNewswire/ -- Chemomab Therapeutics, Ltd. (Nasdaq: CMMB), a...

Aug 12, 2022

─Appoints Ilan Vaknin, PhD, as Vice President of Research & Development and Christina Crater, MD, as Vice President of Clinical Development─ TEL AVIV, Israel, Aug. 12, 2022 /PRNewswire/ --...

Aug 1, 2022

Chemomab Therapeutics Ltd. (Nasdaq: CMMB), (Chemomab), a clinical stage biotechnology company focused on the discovery and development of innovative therapeutics for fibrotic and inflammatory...

Jun 28, 2022

—Covers Use of CM-101 and Sequence-Related Antibodies for the Treatment of Liver Diseases— —Extends Protections Afforded by Composition of Matter and Methods and Use Patents that Have Issued...

All News

Stock Info
NASDAQCMMB
Events
Friday, August 12, 2022
8:00am - 9:00am EDT

Virtual Webcast and Conference Call with Q&A
Senior Management will present
Listen to the Webcast

Conference call information:
US Investors: +1 (877) 407-9208
International Investors: +1 (201) 493-6784
Conference ID: 13730646
Ask for Chemomab conference call.

Thursday, June 23, 2022
4:45pm CEST

Congress information
Oral presentation
Session: Immune-mediated and cholestatic:
Experimental and pathophysiology

All Events

Featured Presentations

Download

Chemomab Corporate Overview - September 2022

 

Annual Report

Download

Chemomab 2021 Annual Report